Evaluation of quality of life in lung cancer patients receiving radiation and Viscum album L.: a real-world data study.
Integrative oncology
Lung cancer
Mistletoe
Multimodal therapy
Non-small-cell lung cancer
Quality of life
Radiotherapy
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
06 Mar 2023
06 Mar 2023
Historique:
received:
18
07
2022
accepted:
20
02
2023
entrez:
6
3
2023
pubmed:
7
3
2023
medline:
9
3
2023
Statut:
epublish
Résumé
Lung cancer (LC) is associated with high mortality and poor quality of life (QoL). The disease as well as oncological treatments such as radiation and chemotherapy with adverse effects can impair the QoL of patients. Add-on treatment with extracts of Viscum album L. (white-berry European mistletoe, VA) has been shown to be feasible and safe and to improve the QoL of cancer patients. The aim of this study was to analyze the changes in QoL of LC patients being treated with radiation according to oncological guidelines and add-on VA treatment in a real-world setting. A real-world data study was conducted using registry data. Self-reported QoL was assessed by the evaluation of the European Organization of Research and Treatment Health-Related Quality of Life Core Questionnaire scale (EORTC QLQ-C30). Adjusted multivariate linear regression analyses were performed to analyze factors associated with changes in QoL at 12 months. A total of 112 primary LC patients (all stages, 92% non-small-cell lung cancer, median age 70 (ICR: 63-75)), answered the questionnaires at first diagnosis and 12 months later. Assessment of 12 months changes in QoL revealed significant improvement of 27 points for pain (p = 0.006) and 17 points for nausea/vomiting (p = 0.005) in patients who received combined radiation and VA. In addition, significant improvements of 15 to 21 points for role (p = 0.03), physical (p = 0.02), cognitive (p = 0.04), and social functioning (p = 0.04) were observed in guideline treated patients receiving no radiation but add-on VA. Add-on VA therapy reveals supportive effects for the QoL of LC patients. Particularly in combination with radiation a significant reduction in pain and nausea/ vomiting has been observed. Trial registration The study received ethics approval and was retrospectively registered (DRKS00013335 on 27/11/2017).
Sections du résumé
BACKGROUND
BACKGROUND
Lung cancer (LC) is associated with high mortality and poor quality of life (QoL). The disease as well as oncological treatments such as radiation and chemotherapy with adverse effects can impair the QoL of patients. Add-on treatment with extracts of Viscum album L. (white-berry European mistletoe, VA) has been shown to be feasible and safe and to improve the QoL of cancer patients. The aim of this study was to analyze the changes in QoL of LC patients being treated with radiation according to oncological guidelines and add-on VA treatment in a real-world setting.
METHODS
METHODS
A real-world data study was conducted using registry data. Self-reported QoL was assessed by the evaluation of the European Organization of Research and Treatment Health-Related Quality of Life Core Questionnaire scale (EORTC QLQ-C30). Adjusted multivariate linear regression analyses were performed to analyze factors associated with changes in QoL at 12 months.
RESULTS
RESULTS
A total of 112 primary LC patients (all stages, 92% non-small-cell lung cancer, median age 70 (ICR: 63-75)), answered the questionnaires at first diagnosis and 12 months later. Assessment of 12 months changes in QoL revealed significant improvement of 27 points for pain (p = 0.006) and 17 points for nausea/vomiting (p = 0.005) in patients who received combined radiation and VA. In addition, significant improvements of 15 to 21 points for role (p = 0.03), physical (p = 0.02), cognitive (p = 0.04), and social functioning (p = 0.04) were observed in guideline treated patients receiving no radiation but add-on VA.
CONCLUSIONS
CONCLUSIONS
Add-on VA therapy reveals supportive effects for the QoL of LC patients. Particularly in combination with radiation a significant reduction in pain and nausea/ vomiting has been observed. Trial registration The study received ethics approval and was retrospectively registered (DRKS00013335 on 27/11/2017).
Identifiants
pubmed: 36879290
doi: 10.1186/s13014-023-02234-3
pii: 10.1186/s13014-023-02234-3
pmc: PMC9990362
doi:
Banques de données
DRKS
['DRKS00013335']
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
47Informations de copyright
© 2023. The Author(s).
Références
BMC Cancer. 2012 Jul 10;12:283
pubmed: 22780988
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Anticancer Res. 2004 Jan-Feb;24(1):303-9
pubmed: 15015612
J Clin Oncol. 2009 Jan 1;27(1):78-84
pubmed: 19047288
Qual Life Res. 2019 Jul;28(7):1849-1861
pubmed: 30825160
PLoS One. 2018 Aug 27;13(8):e0203058
pubmed: 30148853
Evid Based Complement Alternat Med. 2014;2014:430518
pubmed: 24701238
Lung Cancer. 2013 Jul;81(1):11-26
pubmed: 23562675
Psychol Bull. 1992 Jul;112(1):155-9
pubmed: 19565683
Forsch Komplementmed. 2013;20(5):353-60
pubmed: 24200825
Complement Ther Med. 2018 Oct;40:151-157
pubmed: 30219441
J Soc Integr Oncol. 2009 Fall;7(4):137-45
pubmed: 19883529
Evid Based Complement Alternat Med. 2020 May 10;2020:5917382
pubmed: 32454866
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Front Pharmacol. 2017 Jun 15;8:339
pubmed: 28663730
Onco Targets Ther. 2016 Feb 29;9:1023-8
pubmed: 27013895
World J Surg Oncol. 2021 Jun 15;19(1):178
pubmed: 34130688
J Clin Oncol. 2001 Apr 15;19(8):2123-33
pubmed: 11304764
Lung Cancer. 2022 Apr;166:228-241
pubmed: 35334417
Integr Cancer Ther. 2020 Jan-Dec;19:1534735420917211
pubmed: 32478590
Eur J Cancer. 2013 Mar;49(5):1058-64
pubmed: 23218588
BMC Complement Med Ther. 2020 Jul 20;20(1):227
pubmed: 32690087
Lung Cancer. 2017 Nov;113:140-151
pubmed: 29110842
Qual Life Res. 2022 Jul;31(7):1963-1976
pubmed: 35059948
Integr Cancer Ther. 2010 Jun;9(2):142-57
pubmed: 20483874